RAS Inhibitors Enter a New Era as Next-Gen Cancer Drugs Advance
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
3258 articles in this topic
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
Scientists boosted a protein that dampens chronic inflammation, and older mice grew stronger, more energetic, and had healthier bones.
A topical senolytic drug cleared aging 'zombie' cells from old skin, helping aged mice heal wounds 43% more completely by day 24.
A new Cas12a2-based system identifies cancerous or virus-infected cells by their RNA and destroys them โ tested across multiple human cancer lines.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
Insilico Medicine's AI-generated TNIK inhibitor enters Phase 1 trials for pulmonary fibrosis, signaling a new era in drug discovery.
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
A Phase 1b trial shows a daily probiotic capsule may restore immunotherapy response in advanced melanoma patients who had stopped responding.
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
A new GLP-1 therapy engineered to cross the blood-brain barrier enters Phase II trials, targeting cognitive decline in Parkinson's and Alzheimer's.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Matter Bio files first IND for Listeria-based therapy targeting pancreatic cancer, merging oncology and longevity science.